Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7687975 | 0.87 | CYP2D6 (0.48) | CYP2D6MAPK1CA1CA2MMP1 | |
| Pimagedine SCHEMBL1551679 | 0.84 | CYP2D6 (0.55) | CYP2D6MAPK1CA1CA2MMP1 | |
| Hydroxyguanidine SCHEMBL13673553 | 0.84 | CYP2D6 (0.55) | CYP2D6MAPK1CA1CA2MMP1 | |
| SCHEMBL9723332 | 0.83 | ALDH1A1 (0.47) | CYP2D6MAPK1CA1CA2MMP1 | |
| Guanidine SCHEMBL811270 | 0.80 | CYP2D6 (0.61) | CYP2D6MAPK1CA1CA2MMP1 | |
| Hydrazinecarboxamide SCHEMBL5353072 | 0.79 | ALDH1A1 (0.50) | CYP2D6MAPK1CA1CA2MMP1 | |
| Hydrazine SCHEMBL8861759 | 0.78 | ALDH1A1 (0.58) | CYP2D6MAPK1CA1CA2MMP1 | |
| Hno SCHEMBL3391939 | 0.78 | GAA (0.56) | CYP2D6MAPK1CA1CA2MMP1 | |
| Hydroxyamine SCHEMBL599912 | 0.78 | ALDH1A1 (0.58) | CYP2D6MAPK1CA1CA2MMP1 | |
| SCHEMBL29044966 | 0.78 | GAA (0.56) | CYP2D6MAPK1CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4978684-A | ADMINISTERING AMINOGUANIDINE DERIVATIVE | THE ROCKEFELLER UNIVERSITY (US) | 1990-12-18 | — | — | US | claimed |
| US-6599943-B1 | Preventive treatment, related to the radical generating nature of the xanthine dehydrogenase/xanthine oxidase | WAPHARM AB (SE) | 2003-07-29 | — | — | US | disclosed |
| US-6350749-B1 | SODIUM CHANNEL MODULATORS, ANTIARRHYTHMIA AND HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS, ANGINA PECTORIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-02-26 | — | — | US | disclosed |
| EP-1057812-A1 | AMINOGUANIDINE HYDRAZONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-1007025-A1 | USE OF HYDROXYGUANIDINES | Wa Pharm AB (SE) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998023267-A1 | USE OF HYDROXYGUANIDINES | WAPHARM AB (SE) | 1998-06-04 | — | — | WO | disclosed |
| US-5639911-A | Hydrazones | CIBA-GEIGY CORPORATION (US) | 1997-06-17 | — | — | US | disclosed |
| EP-0538193-B1 | Condensed cycloaliphatir-amidino-hydrazon salts as S-adenosylmethionin decarboxylase inhibitors | CIBA GEIGY AG (CH) | 1996-12-04 | — | — | EP | disclosed |
| US-5461076-A | Inhibitors of S-adenosylmethionine decarboxylase; antitumor agents | NOVARTIS CORPORATION | 1995-10-24 | — | — | US | disclosed |
| EP-0456133-B1 | Hydrazones | CIBA GEIGY AG (CH) | 1995-03-15 | — | — | EP | disclosed |
| US-5128122-A | Nitrogen compound | THE ROCKEFELLER UNIVERSITY (US) | 1992-07-07 | — | — | US | disclosed |
| US-5118709-A | Decarboxylase enzyme inhibitors; antitumor agents | CIBA-GEIGY CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| US-5096703-A | Administering aminoguanidine or its salts; oral rinse, tooth paste | THE ROCKEFELLER UNIVERSITY (US) | 1992-03-17 | — | — | US | disclosed |
| EP-0456133-A1 | Hydrazones | CIBA-GEIGY AG (CH) | 1991-11-13 | — | — | EP | disclosed |
| US-4983604-A | Aminoguanidine derivatives | THE ROCKEFELLER UNIVERSITY (US) | 1991-01-08 | — | — | US | disclosed |
| US-4978684-A | ADMINISTERING AMINOGUANIDINE DERIVATIVE | THE ROCKEFELLER UNIVERSITY (US) | 1990-12-18 | — | — | US | disclosed |
| US-4971986-A | ANTITUMOR AGENTS | CIBA-GEIGY CORPORATION (US) | 1990-11-20 | — | — | US | disclosed |
| US-4908446-A | Inhibitors of nonenzymatic cross-linking | THE ROCKEFELLER UNIVERSITY (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0327919-A2 | Method and agents for preventing staining of teeth | THE ROCKEFELLER UNIVERSITY (US) | 1989-08-16 | — | — | EP | disclosed |
| EP-0316852-A2 | Inhibitors of nonenzymatic cross-linking | THE ROCKEFELLER UNIVERSITY (US) | 1989-05-24 | — | — | EP | disclosed |